|
40 Companies |
|
61 Products |
|
61 Products |
|
49 Mechanisms of Action |
|
0 Trials |
|
203 News |
|
| 12345» |
- | Trial completion: Prasterone (Dehydroepiandrosterone) in Treating Postmenopausal Cancer Survivors With Vaginal Symptoms (clinicaltrials.gov) - Feb 7, 2019
P3, N=464, Completed, Sponsor: Alliance for Clinical Trials in Oncology
Active, not recruiting --> Completed
- | Trial completion date, Trial primary completion date: DNA Analysis in Samples From Younger Patients With Germ Cell Tumors and Their Parents or Siblings (clinicaltrials.gov) - Jan 7, 2019
P=N/A, N=932, Completed, Sponsor: Children's Oncology Group
Active, not recruiting --> Completed Trial completion date: Mar 2013 --> Aug 2016 | Trial primary completion date: Mar 2013 --> Aug 2016
- | Clinical protocol, Trial completion, Trial completion date, Trial primary completion date: Glycan Analysis in Diagnosing Cancer in Women With Ovarian Epithelial Cancer and in Healthy Female Participants (clinicaltrials.gov) - Jan 4, 2019
P=N/A, N=581, Completed, Sponsor: University of California, Davis
Trial completion date: Mar 2013 --> Aug 2016 | Trial primary completion date: Mar 2013 --> Aug 2016 Recruiting --> Completed | Trial completion date: Dec 2019 --> Mar 2016 | Trial primary completion date: Dec 2018 --> Mar 2016
- |||| Rubraca (rucaparib) / Pharma& Schweiz
Trial completion, Trial primary completion date, BRCA Biomarker, PARP Biomarker, Metastases: CRUK-PARP/BRCA: Rucaparib(CO-338;Formally Called AG-014699 or PF-0136738) in Treating Patients With Locally Advanced or Metastatic Breast Cancer or Advanced Ovarian Cancer (clinicaltrials.gov) - Jan 3, 2019
P2, N=78, Completed, Sponsor: Cancer Research UK
Recruiting --> Completed | Trial completion date: Dec 2019 --> Mar 2016 | Trial primary completion date: Dec 2018 --> Mar 2016 Active, not recruiting --> Completed | Trial primary completion date: Sep 2014 --> Jan 2015
- veliparib (ABT-888) / AbbVie
Trial termination, Combination therapy, BRCA Biomarker, PARP Biomarker, Metastases: Veliparib, Oxaliplatin, and Capecitabine in Treating Patients With Advanced Solid Tumors (clinicaltrials.gov) - Jan 3, 2019
P1, N=16, Terminated, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed | Trial primary completion date: Sep 2014 --> Jan 2015 Active, not recruiting --> Terminated
- | Trial completion date: Combination Chemotherapy in Treating Young Patients With Recurrent or Resistant Malignant Germ Cell Tumors (clinicaltrials.gov) - Aug 28, 2018
P2, N=20, Completed, Sponsor: Children's Oncology Group
Active, not recruiting --> Terminated Trial completion date: Mar 2012 --> Jun 2018
- | Trial completion date, Trial termination: Genetic Susceptibility and Risk of Second Cancers in Patients Who Have Undergone Stem Cell Transplant for Cancer (clinicaltrials.gov) - Aug 16, 2018
P=N/A, N=1000, Terminated, Sponsor: Vanderbilt-Ingram Cancer Center
Trial completion date: Mar 2012 --> Jun 2018 Trial completion date: Dec 2020 --> Feb 2018 | Active, not recruiting --> Terminated; Low accrual
- | Trial completion: DNA Analysis in Samples From Younger Patients With Germ Cell Tumors and Their Parents or Siblings (clinicaltrials.gov) - Aug 7, 2018
P=N/A, N=932, Completed, Sponsor: Children's Oncology Group
Trial completion date: Dec 2020 --> Feb 2018 | Active, not recruiting --> Terminated; Low accrual Recruiting --> Completed
- | Trial completion: Psychosexual Intervention in Patients With Stage I-III Gynecologic or Breast Cancer (clinicaltrials.gov) - Jun 1, 2018
P2, N=100, Completed, Sponsor: Ohio State University Comprehensive Cancer Center
Recruiting --> Completed Recruiting --> Completed
- | Trial completion: Changes in Brain Function in Patients With Stage I, Stage II, Stage III, or Stage IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Who Are Receiving Chemotherapy (clinicaltrials.gov) - Apr 12, 2018
P=N/A, N=247, Completed, Sponsor: Gynecologic Oncology Group
Recruiting --> Completed Active, not recruiting --> Completed
- | Clinical protocol, Trial primary completion date: Glycan Analysis in Diagnosing Cancer in Women With Ovarian Epithelial Cancer and in Healthy Female Participants (clinicaltrials.gov) - Jan 5, 2018
P=N/A, N=700, Recruiting, Sponsor: University of California, Davis
Active, not recruiting --> Completed Trial primary completion date: Dec 2017 --> Dec 2018
- | NN1213 / Novo Nordisk
Enrollment change, Trial initiation date, Trial termination, Metastases: Antineoplaston Therapy in Treating Patients With Stage III or Stage IV Ovarian Cancer (clinicaltrials.gov) - Dec 12, 2017
P2, N=7, Terminated, Sponsor: Burzynski Research Institute
Trial primary completion date: Dec 2017 --> Dec 2018 N=40 --> 7 | Initiation date: Aug 1998 --> Mar 1996 | Active, not recruiting --> Terminated; Slow accrual
- pegylated liposomal doxorubicin / Generic mfg., carboplatin / Generic mfg.
Enrollment change, Trial withdrawal: Doxorubicin and Carboplatin in Treating Patients With Recurrent Ovarian Cancer (clinicaltrials.gov) - Nov 20, 2017
P1/2, N=0, Withdrawn, Sponsor: University of Texas Southwestern Medical Center
N=40 --> 7 | Initiation date: Aug 1998 --> Mar 1996 | Active, not recruiting --> Terminated; Slow accrual N=61 --> 0 | Completed --> Withdrawn
- | Trial completion: Combination Chemotherapy in Treating Young Patients With Recurrent or Resistant Malignant Germ Cell Tumors (clinicaltrials.gov) - Nov 9, 2017
P2, N=20, Completed, Sponsor: Children's Oncology Group
N=61 --> 0 | Completed --> Withdrawn Active, not recruiting --> Completed
- | Trial completion, Phase classification, Enrollment change, Trial primary completion date, Surgery: Contrast-Enhanced Ultrasonography in Diagnosing Early-Stage Ovarian Cancer in Patients With an Adnexal Mass Undergoing Surgery to Remove the Ovary (clinicaltrials.gov) - Apr 18, 2017
P1, N=67, Completed, Sponsor: Icahn School of Medicine at Mount Sinai
Active, not recruiting --> Completed Recruiting --> Completed | Phase classification: PN/A --> P1 | N=100 --> 67 | Trial primary completion date: Jan 2013 --> Feb 2012
- | Trial primary completion date: Psychosexual Intervention in Patients With Stage I-III Gynecologic or Breast Cancer (clinicaltrials.gov) - Apr 13, 2017
P2, N=100, Recruiting, Sponsor: Ohio State University Comprehensive Cancer Center
Recruiting --> Completed | Phase classification: PN/A --> P1 | N=100 --> 67 | Trial primary completion date: Jan 2013 --> Feb 2012 Trial primary completion date: Aug 2016 --> Aug 2018
- | Trial completion: Yoga in Controlling Symptoms and Reducing Stress in Women With Ovarian Cancer or Breast Cancer (clinicaltrials.gov) - Apr 7, 2017
P=N/A, N=106, Completed, Sponsor: Wake Forest University Health Sciences
Trial primary completion date: Aug 2016 --> Aug 2018 Active, not recruiting --> Completed
- | Enrollment closed, Trial primary completion date: Genetic Susceptibility and Risk of Second Cancers in Patients Who Have Undergone Stem Cell Transplant for Cancer (clinicaltrials.gov) - Feb 23, 2017
P=N/A, N=1000, Active, not recruiting, Sponsor: Vanderbilt University Medical Center
Active, not recruiting --> Completed Recruiting --> Active, not recruiting | Trial primary completion date: Jan 2014 --> Dec 2014
- Trial termination: Lactobacillus in Preventing Infection in Patients Undergoing a Donor Stem Cell Transplant for Hematologic Cancer or Myelodysplastic Syndrome (clinicaltrials.gov) - Feb 3, 2017
P=N/A, N=30, Terminated, Sponsor: Rutgers, The State University of New Jersey
Recruiting --> Active, not recruiting | Trial primary completion date: Jan 2014 --> Dec 2014 Active, not recruiting --> Terminated; slow accrual
- Trial completion, Trial initiation date, Metastases: Massage Therapy in Treating the Symptoms of Patients With Locally Advanced or Metastatic Cancer (clinicaltrials.gov) - Jan 30, 2017
P=N/A, N=42, Completed, Sponsor: Beth Israel Deaconess Medical Center
Active, not recruiting --> Terminated; slow accrual Active, not recruiting --> Completed | Initiation date: Dec 2003 --> Dec 2004
- Trial completion: High-dose ICE With Amifostine (clinicaltrials.gov) - Jan 23, 2017
P2, N=24, Completed, Sponsor: Dana-Farber Cancer Institute
Active, not recruiting --> Completed | Initiation date: Dec 2003 --> Dec 2004 Active, not recruiting --> Completed
- | Trial completion: Carboplatin, Etoposide, Cyclophosphamide, and Autologous Bone Marrow Transplantation in Patients With Relapsed or Refractory Cancer (clinicaltrials.gov) - Jan 18, 2017
P2, N=11, Completed, Sponsor: Wake Forest University Health Sciences
Active, not recruiting --> Completed No longer recruiting --> Completed
- Clinical protocol, Trial primary completion date: Glycan Analysis in Diagnosing Cancer in Women With Ovarian Epithelial Cancer and in Healthy Female Participants (clinicaltrials.gov) - Dec 22, 2016
P=N/A, N=700, Recruiting, Sponsor: University of California, Davis
No longer recruiting --> Completed Trial primary completion date: Dec 2016 --> Dec 2017
- Trial completion: Study of Physical and Psychosocial Rehabilitation Needs of Patients After Diagnosis and Treatment of Upper Gastrointestinal Cancer or Gynecological Cancer (clinicaltrials.gov) - Nov 1, 2016
P=N/A, N=33, Completed, Sponsor: Royal Marsden NHS Foundation Trust
Trial primary completion date: Dec 2016 --> Dec 2017 Recruiting --> Completed
- Trial completion, Trial primary completion date, Adverse events: Low-Fiber Diet or High-Fiber Diet in Preventing Bowel Side Effects in Patients Undergoing Radiation Therapy for Gynecological Cancer, Bladder Cancer, Colorectal Cancer, or Anal Cancer (clinicaltrials.gov) - Nov 1, 2016
P=N/A, N=177, Completed, Sponsor: Royal Marsden NHS Foundation Trust
Recruiting --> Completed Recruiting --> Completed | Trial primary completion date: Apr 2012 --> Dec 2012
- Trial completion: Collecting Tumor Samples From Patients With Gynecological Tumors (clinicaltrials.gov) - Oct 28, 2016
P=N/A, N=275, Completed, Sponsor: Gynecologic Oncology Group
Recruiting --> Completed | Trial primary completion date: Apr 2012 --> Dec 2012 Recruiting --> Completed
- || Trial primary completion date: DNA Analysis in Samples From Younger Patients With Germ Cell Tumors and Their Parents or Siblings (clinicaltrials.gov) - Oct 11, 2016
P=N/A, N=932, Recruiting, Sponsor: Children's Oncology Group
Recruiting --> Completed Trial primary completion date: Aug 2016 --> Aug 2018
- sirolimus / Generic mfg.
Trial completion, Enrollment change: Vaccine Therapy With or Without Sirolimus in Treating Patients With NY-ESO-1 Expressing Solid Tumors (clinicaltrials.gov) - Oct 4, 2016
P1, N=18, Completed, Sponsor: Roswell Park Cancer Institute
Trial primary completion date: Aug 2016 --> Aug 2018 Active, not recruiting --> Completed | N=30 --> 18
- | Trial completion, Trial primary completion date, Stroma: Studying Genes in Samples From Younger Patients With Ovarian or Testicular Sex Cord Stromal Tumors (clinicaltrials.gov) - Jul 14, 2016
P=N/A, N=50, Completed, Sponsor: Children's Oncology Group
Active, not recruiting --> Completed | N=30 --> 18 Active, not recruiting --> Completed | Trial primary completion date: Jan 2100 --> Jul 2016
- | NN1213 / Novo Nordisk
Trial completion: Octreotide in Preventing Diarrhea in Patients Who Are Undergoing Radiation Therapy to the Pelvis (clinicaltrials.gov) - Jul 11, 2016
P3, N=130, Completed, Sponsor: Alliance for Clinical Trials in Oncology
Active, not recruiting --> Completed | Trial primary completion date: Jan 2100 --> Jul 2016 Active, not recruiting --> Completed
- cisplatin / Generic mfg.
Trial termination: Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Germ Cell Tumors (clinicaltrials.gov) - Jun 23, 2016
P2, N=45, Terminated, Sponsor: UNICANCER
Active, not recruiting --> Completed Active, not recruiting --> Terminated; lack of patient inclusion
- Neulasta (pegfilgrastim) / Roche
Trial completion, Trial primary completion date: Combination Chemotherapy and Pegfilgrastim in Treating Patients With Previously Untreated Germ Cell Tumors (clinicaltrials.gov) - Jun 19, 2016
P2, N=60, Completed, Sponsor: Memorial Sloan Kettering Cancer Center
Active, not recruiting --> Terminated; lack of patient inclusion Active, not recruiting --> Completed | Trial primary completion date: Sep 2016 --> Jun 2016
- | Torisel (temsirolimus) / Pfizer
Trial completion, Metastases: Temsirolimus and Vinorelbine Ditartrate in Treating Patients With Unresectable or Metastatic Solid Tumors (clinicaltrials.gov) - Jun 13, 2016
P1, N=19, Completed, Sponsor: University of Southern California
Active, not recruiting --> Completed | Trial primary completion date: Sep 2016 --> Jun 2016 Active, not recruiting --> Completed
- | Trial completion: Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Germ Cell Tumors (clinicaltrials.gov) - Jun 13, 2016
P1/2, N=108, Completed, Sponsor: Memorial Sloan Kettering Cancer Center
Active, not recruiting --> Completed Recruiting --> Completed
- | Zaltrap (ziv-aflibercept IV) / Sanofi
Trial completion, Metastases: Intravenous VEGF Trap in Treating Patients With Relapsed or Refractory Advanced Solid Tumors or Non-Hodgkin's Lymphoma (clinicaltrials.gov) - Jun 8, 2016
P1, N=25, Completed, Sponsor: Regeneron Pharmaceuticals
Recruiting --> Completed Active, not recruiting --> Completed
- | Zaltrap (ziv-aflibercept IV) / Sanofi
Trial completion, Metastases: Intravenous VEGF Trap in Treating Patients With Relapsed or Refractory Advanced Solid Tumors or Non-Hodgkin's Lymphoma (clinicaltrials.gov) - Jun 8, 2016
P1, N=25, Completed, Sponsor: Regeneron Pharmaceuticals
Active, not recruiting --> Completed Active, not recruiting --> Completed
- ||| Biomarker, Trial completion, Trial primary completion date: Studying Biomarkers in Samples From Younger Patients With Malignant Germ Cell Tumor Progression (clinicaltrials.gov) - May 19, 2016
P=N/A, N=90, Completed, Sponsor: Children's Oncology Group
Active, not recruiting --> Completed Active, not recruiting --> Completed | Trial primary completion date: Jan 2100 --> May 2016
- || Trial primary completion date: DNA Analysis in Samples From Younger Patients With Germ Cell Tumors and Their Parents or Siblings (clinicaltrials.gov) - Apr 9, 2016
P=N/A, N=932, Recruiting, Sponsor: Children's Oncology Group
Active, not recruiting --> Completed | Trial primary completion date: Jan 2100 --> May 2016 Trial primary completion date: Nov 2015 --> Aug 2016
- Clinical protocol, Trial primary completion date: Glycan Analysis in Diagnosing Cancer in Women With Ovarian Epithelial Cancer and in Healthy Female Participants (clinicaltrials.gov) - Jan 22, 2016
P=N/A, N=700, Recruiting, Sponsor: University of California, Davis
Trial primary completion date: Nov 2015 --> Aug 2016 Trial primary completion date: Dec 2014 --> Dec 2016
- pemetrexed / Generic mfg., docetaxel / Generic mfg.
Trial completion, Enrollment change, Trial primary completion date, Combination therapy, Metastases: Pemetrexed Disodium and Docetaxel in Treating Patients With Advanced Solid Tumors (clinicaltrials.gov) - Dec 5, 2015
P1, N=33, Completed, Sponsor: University of Arizona
Trial primary completion date: Dec 2014 --> Dec 2016 Active, not recruiting --> Completed | N=54 --> 33 | Trial primary completion date: Apr 2014 --> Jul 2014
- | arsenic trioxide / Generic mfg.
Trial completion, Metastases: Arsenic Trioxide in Treating Patients With Advanced Neuroblastoma or Other Childhood Solid Tumors (clinicaltrials.gov) - Nov 24, 2015
P2, N=22, Completed, Sponsor: Memorial Sloan Kettering Cancer Center
Active, not recruiting --> Completed | N=54 --> 33 | Trial primary completion date: Apr 2014 --> Jul 2014 Suspended --> Completed
- sirolimus / Generic mfg.
Enrollment change: Vaccine Therapy With or Without Sirolimus in Treating Patients With NY-ESO-1 Expressing Solid Tumors (clinicaltrials.gov) - Nov 15, 2015
P1, N=30, Active, not recruiting, Sponsor: Roswell Park Cancer Institute
Suspended --> Completed N=18 --> 30
- albumin-bound paclitaxel / Generic mfg.
Biomarker, Enrollment change, Metastases: Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Advanced or Refractory Solid Tumors (clinicaltrials.gov) - Oct 22, 2015
P=N/A, N=0, Withdrawn, Sponsor: Eastern Cooperative Oncology Group
N=18 --> 30 N=129 --> 0
- Trial completion, Trial primary completion date, HEOR: Stress Reduction in Improving Quality of Life in Patients With Recurrent Gynecologic or Breast Cancer (clinicaltrials.gov) - Oct 9, 2015
P=N/A, N=39, Completed, Sponsor: Ohio State University Comprehensive Cancer Center
N=129 --> 0 Active, not recruiting --> Completed | Trial primary completion date: Jul 2015 --> Jan 2012
- Trial primary completion date: Prasterone (Dehydroepiandrosterone) in Treating Postmenopausal Cancer Survivors With Vaginal Symptoms (clinicaltrials.gov) - Sep 25, 2015
P3, N=464, Active, not recruiting, Sponsor: Alliance for Clinical Trials in Oncology
Active, not recruiting --> Completed | Trial primary completion date: Jul 2015 --> Jan 2012 Trial primary completion date: Aug 2020 --> Aug 2013
- Neulasta (pegfilgrastim) / Roche
Trial primary completion date: Combination Chemotherapy and Pegfilgrastim in Treating Patients With Previously Untreated Germ Cell Tumors (clinicaltrials.gov) - Aug 17, 2015
P2, N=55, Active, not recruiting, Sponsor: Memorial Sloan Kettering Cancer Center
Trial primary completion date: Aug 2020 --> Aug 2013 Trial primary completion date: Sep 2015 --> Sep 2016
- Trial primary completion date: Prasterone (Dehydroepiandrosterone) in Treating Postmenopausal Cancer Survivors With Vaginal Symptoms (clinicaltrials.gov) - Aug 13, 2015
P3, N=464, Active, not recruiting, Sponsor: Alliance for Clinical Trials in Oncology
Trial primary completion date: Sep 2015 --> Sep 2016 Trial primary completion date: Aug 2014 --> Aug 2020
- carboplatin / Generic mfg., gemcitabine / Generic mfg.
Trial completion, Surgery: Carboplatin, Gemcitabine Hydrochloride, and Stereotactic Body Radiation Therapy in Gynecological Cancer (clinicaltrials.gov) - Aug 12, 2015
P1, N=12, Completed, Sponsor: Case Comprehensive Cancer Center
Trial primary completion date: Aug 2014 --> Aug 2020 Active, not recruiting --> Completed
- Enrollment open, Enrollment change, Trial primary completion date: Psychosexual Intervention in Patients With Stage I-III Gynecologic or Breast Cancer (clinicaltrials.gov) - Aug 11, 2015
P2, N=100, Recruiting, Sponsor: Ohio State University Comprehensive Cancer Center
Active, not recruiting --> Completed Active, not recruiting --> Recruiting | N=60 --> 100 | Trial primary completion date: Sep 2015 --> Aug 2016
- capecitabine / Generic mfg.
Trial completion: Chemotherapy Plus Radiation Therapy in Treating Patients With Unresectable, Residual, or Recurrent Colorectal Cancer (clinicaltrials.gov) - Jul 16, 2015
P1, N=51, Completed, Sponsor: Alliance for Clinical Trials in Oncology
Active, not recruiting --> Recruiting | N=60 --> 100 | Trial primary completion date: Sep 2015 --> Aug 2016 Active, not recruiting --> Completed